BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

BACKGROUND: Patients with cardiovascular disease (CVD) and type 2 diabetes (DM2) have a high residual risk for experiencing a major adverse cardiac event. Dysregulation of epigenetic mechanisms of gene transcription in innate immune cells contributes to CVD development but is currently not targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasiak, Sylwia, Dzobo, Kim E., Rakai, Brooke D., Kaiser, Yannick, Versloot, Miranda, Bahjat, Mahnoush, Stotz, Stephanie C., Fu, Li, Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Stroes, Erik S. G., Kroon, Jeffrey, Kulikowski, Ewelina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657365/
https://www.ncbi.nlm.nih.gov/pubmed/33172487
http://dx.doi.org/10.1186/s13148-020-00943-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657365/
https://www.ncbi.nlm.nih.gov/pubmed/33172487
http://dx.doi.org/10.1186/s13148-020-00943-0

Ejemplares similares